Pfizer Sticking To “Plan A,” But Read Says That Doesn’t Require AstraZeneca
This article was originally published in The Pink Sheet Daily
If Pfizer’s ambition to grow through a combination with AstraZeneca doesn’t come to pass, there is no Plan B, CEO Ian Read says during the big pharma’s second quarter earnings call.
You may also be interested in...
Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.